Boundless Bio Appoints Peter Krein, Ph.D., as Vice President, Precision Medicine

- Dr. Krein has over 15 years of experience at diagnostic and pharmaceutical companies and has a successful track record of developing and commercializing companion diagnostics in oncology -

Boundless Bio, a next-generation precision oncology company developing innovative therapeutics directed against extrachromosomal DNA (ecDNA) in aggressive cancers, today announced that Peter Krein has been appointed as Vice President of Precision Medicine.

“We are thrilled to welcome Peter to our growing team,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. “He brings a wealth of expertise in precision medicine strategy and companion diagnostic development, which will be extremely valuable as we work to advance our innovative ecDNA-directed precision oncology therapeutics through preclinical validation, clinical development, and commercialization.”

Previously, Peter served as Executive Director, Diagnostic Development and Medical Affairs at Loxo Oncology at Lilly, where he led global diagnostic strategies for precision oncology therapeutics. Prior to Loxo Oncology, Dr. Krein spent two years as Managing Director at Diaceutics Group, where he advised several global pharmaceutical companies on effective integration of diagnostics into drug development and commercialization strategies. Prior to Diaceutics, Peter held leadership roles developing in vitro diagnostics and companion diagnostics at Qiagen, GenMark Diagnostics, Luminex Corporation, and Roche Tissue Diagnostics. He holds a Ph.D. in Molecular Immunology & Oncology from the University of Calgary and completed a postdoctoral fellowship in functional genomics at the University of Arizona.

“I am honored to join Boundless Bio at such an exciting stage of the company,” said Dr. Krein. “Oncogenic gene amplifications have been observed in a variety of tumor types both as primary driver events and mechanisms by which tumors evade current treatment approaches and thus represent an area of high unmet need. I look forward to contributing to Boundless Bio’s precision oncology strategy and capabilities to treat patients with ecDNA driven gene amplification.”

About Boundless Bio

Boundless Bio is a next-generation precision oncology company interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

For more information, visit www.boundlessbio.com.

Follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220117005012/en/